[go: up one dir, main page]

MX2012002209A - Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos. - Google Patents

Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.

Info

Publication number
MX2012002209A
MX2012002209A MX2012002209A MX2012002209A MX2012002209A MX 2012002209 A MX2012002209 A MX 2012002209A MX 2012002209 A MX2012002209 A MX 2012002209A MX 2012002209 A MX2012002209 A MX 2012002209A MX 2012002209 A MX2012002209 A MX 2012002209A
Authority
MX
Mexico
Prior art keywords
controlled
release formulations
anabaseine
anabaseine compounds
compounds
Prior art date
Application number
MX2012002209A
Other languages
English (en)
Inventor
William Reade Kem
Ferenc Soti
Robert Freedman
Lynn Johnson
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2012002209A publication Critical patent/MX2012002209A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formas de dosis de liberación controlada de compuestos de anabaseina, tales como 3-(2,4-dimetoxibenciliden)-anabaseina (también conocido como DMXB o GTS-21) o una sal farmacéuticamente aceptable de los mismos, métodos de uso, y métodos para producir las formas de dosis de liberación controlada.
MX2012002209A 2009-08-21 2010-08-18 Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos. MX2012002209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23587609P 2009-08-21 2009-08-21
PCT/US2010/045867 WO2011022467A2 (en) 2009-08-21 2010-08-18 Controlled-release formulations of anabaseine compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2012002209A true MX2012002209A (es) 2012-07-25

Family

ID=43607570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002209A MX2012002209A (es) 2009-08-21 2010-08-18 Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.

Country Status (7)

Country Link
US (1) US20120237563A1 (es)
EP (1) EP2467131A4 (es)
JP (1) JP2013502427A (es)
KR (1) KR20120054639A (es)
AU (1) AU2010284282A1 (es)
MX (1) MX2012002209A (es)
WO (1) WO2011022467A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
EP2611788B1 (en) 2010-09-03 2017-04-12 University of Florida Research Foundation, Incorporated Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
CA2809675A1 (en) 2010-09-23 2012-03-29 Shuang Chen Monohydrate of an azaadamantane derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0175638B1 (ko) * 1991-03-01 1999-02-18 카렌 에이.홀브루크 신경계 퇴행성 질환 치료용 니코틴 아날로그의 개량된 제조방법
EP0659078B1 (en) * 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US20060111382A1 (en) * 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet

Also Published As

Publication number Publication date
EP2467131A2 (en) 2012-06-27
WO2011022467A2 (en) 2011-02-24
KR20120054639A (ko) 2012-05-30
JP2013502427A (ja) 2013-01-24
AU2010284282A1 (en) 2012-04-12
EP2467131A4 (en) 2014-02-19
WO2011022467A3 (en) 2011-06-30
US20120237563A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
SG179120A1 (en) Novel compounds
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MY181898A (en) Heterocyclic compounds and uses thereof
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
IL192948A0 (en) Novel pyridine derivatives
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
EA201170703A1 (ru) Производные адамантилбензамида
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
TN2012000031A1 (en) Tablet
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
SE0800742L (sv) Vikttäcke
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.